Literature DB >> 12857909

Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.

Simone Hornemann1, Olof Harlin, Caroline Staib, Sigrid Kisling, Volker Erfle, Bernd Kaspers, Georg Häcker, Gerd Sutter.   

Abstract

Highly attenuated modified vaccinia virus Ankara (MVA) serves as a candidate vaccine to immunize against infectious diseases and cancer. MVA was randomly obtained by serial growth in cultures of chicken embryo fibroblasts (CEF), resulting in the loss of substantial genomic information including many genes regulating virus-host interactions. The vaccinia virus interferon (IFN) resistance gene E3L is among the few conserved open reading frames encoding viral immune defense proteins. To investigate the relevance of E3L in the MVA life cycle, we generated the deletion mutant MVA-DeltaE3L. Surprisingly, we found that MVA-DeltaE3L had lost the ability to grow in CEF, which is the first finding of a vaccinia virus host range phenotype in this otherwise highly permissive cell culture. Reinsertion of E3L led to the generation of revertant virus MVA-E3rev and rescued productive replication in CEF. Nonproductive infection of CEF with MVA-DeltaE3L allowed viral DNA replication to occur but resulted in an abrupt inhibition of viral protein synthesis at late times. Under these nonpermissive conditions, CEF underwent apoptosis starting as early as 6 h after infection, as shown by DNA fragmentation, Hoechst staining, and caspase activation. Moreover, we detected high levels of active chicken alpha/beta IFN (IFN-alpha/beta) in supernatants of MVA-DeltaE3L-infected CEF, while moderate IFN quantities were found after MVA or MVA-E3rev infection and no IFN activity was present upon infection with wild-type vaccinia viruses. Interestingly, pretreatment of CEF with similar amounts of recombinant chicken IFN-alpha inhibited growth of vaccinia viruses, including MVA. We conclude that efficient propagation of MVA in CEF, the tissue culture system used for production of MVA-based vaccines, essentially requires conserved E3L gene function as an inhibitor of apoptosis and/or IFN induction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12857909      PMCID: PMC165266          DOI: 10.1128/jvi.77.15.8394-8407.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  72 in total

1.  The vaccinia virus E3L gene product interacts with both the regulatory and the substrate binding regions of PKR: implications for PKR autoregulation.

Authors:  T V Sharp; F Moonan; A Romashko; B Joshi; G N Barber; R Jagus
Journal:  Virology       Date:  1998-10-25       Impact factor: 3.616

2.  Cloning and expression of foreign genes in vaccinia virus, using a host range selection system.

Authors:  M E Perkus; K Limbach; E Paoletti
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

3.  Convenient assay for interferons.

Authors:  S Rubinstein; P C Familletti; S Pestka
Journal:  J Virol       Date:  1981-02       Impact factor: 5.103

4.  Resistance of vaccinia virus to interferon is related to an interference phenomenon between the virus and the interferon system.

Authors:  E Paez; M Esteban
Journal:  Virology       Date:  1984-04-15       Impact factor: 3.616

Review 5.  Cell death: the significance of apoptosis.

Authors:  A H Wyllie; J F Kerr; A R Currie
Journal:  Int Rev Cytol       Date:  1980

6.  Development of the interferon system. I. In chicken cells development in ovo continues on time in vitro.

Authors:  M J Sekellick; W J Biggers; P I Marcus
Journal:  In Vitro Cell Dev Biol       Date:  1990-10

7.  Studies on poxvirus infections in irradiated animals.

Authors:  G T Werner; U Jentzsch; E Metzger; J Simon
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

8.  Dominant host range selection of vaccinia recombinants by rescue of an essential gene.

Authors:  G W Holzer; W Gritschenberger; J A Mayrhofer; V Wieser; F Dorner; F G Falkner
Journal:  Virology       Date:  1998-09-15       Impact factor: 3.616

9.  A cowpox virus gene required for multiplication in Chinese hamster ovary cells.

Authors:  D Spehner; S Gillard; R Drillien; A Kirn
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

10.  Vaccinia rescue of VSV from interferon-induced resistance: reversal of translation block and inhibition of protein kinase activity.

Authors:  P Whitaker-Dowling; J S Youngner
Journal:  Virology       Date:  1983-11       Impact factor: 3.616

View more
  28 in total

1.  Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene.

Authors:  José Luis Nájera; Carmen Elena Gómez; Elena Domingo-Gil; María Magdalena Gherardi; Mariano Esteban
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 2.  Viruses as vaccine vectors for infectious diseases and cancer.

Authors:  Simon J Draper; Jonathan L Heeney
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

3.  Induction of apoptosis limits cytomegalovirus cross-species infection.

Authors:  Igor Jurak; Wolfram Brune
Journal:  EMBO J       Date:  2006-05-11       Impact factor: 11.598

4.  Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors.

Authors:  Xiugen Zhang; Farah Cassis-Ghavami; Mike Eller; Jeff Currier; Bonnie M Slike; Xuemin Chen; James Tartaglia; Mary Marovich; Paul Spearman
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

5.  Generation of a complete single-gene knockout bacterial artificial chromosome library of cowpox virus and identification of its essential genes.

Authors:  Zhiyong Xu; Dimitrios Zikos; Nikolaus Osterrieder; B Karsten Tischer
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

6.  Role of viral factor E3L in modified vaccinia virus ankara infection of human HeLa Cells: regulation of the virus life cycle and identification of differentially expressed host genes.

Authors:  Holger Ludwig; Jörg Mages; Caroline Staib; Michael H Lehmann; Roland Lang; Gerd Sutter
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

7.  Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.

Authors:  Naif Khalaf Alharbi; Alexandra J Spencer; Adrian V S Hill; Sarah C Gilbert
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

8.  Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components.

Authors:  Zoe Waibler; Martina Anzaghe; Theresa Frenz; Astrid Schwantes; Christopher Pöhlmann; Holger Ludwig; Marcos Palomo-Otero; Antonio Alcamí; Gerd Sutter; Ulrich Kalinke
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

9.  The orthopoxvirus 68-kilodalton ankyrin-like protein is essential for DNA replication and complete gene expression of modified vaccinia virus Ankara in nonpermissive human and murine cells.

Authors:  Karin M Sperling; Astrid Schwantes; Caroline Staib; Barbara S Schnierle; Gerd Sutter
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

10.  Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.

Authors:  Joseph N Brewoo; Tim D Powell; Jeremy C Jones; Nancy A Gundlach; Ginger R Young; Haiyan Chu; Subash C Das; Charalambos D Partidos; Dan T Stinchcomb; Jorge E Osorio
Journal:  Vaccine       Date:  2013-02-01       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.